RCKTMEDIUM SIGNALFINANCIAL10-K

Rocket Pharmaceuticals shows signs of operational improvement with reduced losses and expenses, but faces mounting cash burn concerns with cash reserves falling 52.6% to $77.6M.

While the company demonstrated cost discipline by reducing R&D expenses 17% and improving operating losses by 15%, the dramatic decline in cash position raises questions about runway duration. The strategic restructuring mentioned in risk factors appears to be yielding some benefits, but the sustainability of operations depends on securing additional funding or further cost reductions.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

Rocket's financial profile reflects a company in active cost management mode, with R&D expenses declining 17% and overall losses improving meaningfully (operating loss improved 15% and net loss improved 14%). However, the company's cash position deteriorated significantly, falling from $163.6M to $77.6M, while current assets dropped 49% and stockholders' equity declined 40%. The dramatic 92.5% reduction in capital expenditures to just $440K, combined with the substantial cash burn, signals a company prioritizing cash preservation while maintaining core operations.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-92.5%
$5.9M→$440K

Capex reduced 92.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-52.6%
$163.6M→$77.6M

Cash declined 52.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-49%
$378.2M→$192.7M

Current assets declined 49% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-40.2%
$463.2M→$277.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Assets
Balance Sheet
-37.4%
$527.7M→$330.4M

Total assets contracted 37.4% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
-25.8%
$40.7M→$30.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-17.4%
$64.5M→$53.2M

Liabilities reduced 17.4% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-17.1%
$171.2M→$142.0M

R&D spending cut 17.1% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+15.2%
-$273.2M→-$231.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+13.8%
-$258.7M→-$223.1M

Net income grew 13.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As o f February 20, 2026, there were 108,569,143 s hares of common stock, $0.01 par value per share, outstanding.
Form 10-K Summary 81 Signatures 82 3 Summary of Abbreviated Terms Rocket Pharmaceuticals, Inc.
may be referred to as Rocket, the Company, we, our or us, in this Annual Report on Form 10-K (the Annual Report ), unless the context otherwise indicates.
acquired on December 1, 2022 DD Danon Disease RIF Reduction in workforce DNA Deoxyribonucleic acid RMAT Regenerative Medicine Advanced Therapy EMA European Medicines Agency RSU Restricted Stock Unit ESB Lease Agreement Office Lease agreement for office space in the Empire State Building in New York City RTW RTW Investments, L.P EU European Union SAE Serious Adverse Event FA Fanconi Anemia SCD Sudden cardiac death FDA U.S.
These forward-looking statements include, but are not limited to, statements about: our ability to obtain additional funding to conduct our planned research and development efforts; our ability to meet our anticipated milestones for our various drug candidates with respect to the initiation and timing of clinical studies; federal, state, and non-U.S.
These risks and uncertainties include, but are not limited to, the following: Our strategic restructuring may not result in the savings we anticipate, could result in total costs and expenses that are greater than expected and could disrupt our operations.
We are and may continue to be targets of securities-related class action and derivative lawsuits and defending against these claims could result in substantial costs and divert management time and resources and have a material adverse effect on our results of operations.
We have a history of operating losses, and we may not achieve or sustain profitability.
We anticipate that we will continue to incur losses for the foreseeable future.
Our limited operating history may make it difficult for us to evaluate the success of our business to date and to assess our future viability.
REMOVED
As of February 21, 2025, there were 106,629,701 shares of common stock, $0.01 par value per share, outstanding.
Form 10-K Summary 89 Signatures 90 3 Summary of Abbreviated Terms Rocket Pharmaceuticals, Inc.
may be referred to as Rocket, the Company, we, our or us, in this Annual Report, unless the context otherwise indicates.
Throughout this Annual Report, we have used terms which are defined below: AAV Adeno-associated virus GLP Good Laboratory Practice ACA Affordable Care Act GMP Good Manufacturing Practice ACM Arrhythmogenic cardiomyopathy HIPAA Health Insurance Portability and Accountability Act ASC Accounting Standard Codification HHS U.S.
acquired on December 1, 2022 DNA Deoxyrubonucleic acid RMAT Regenerative Medicine Advanced Therapy EMA European Medicines Agency RSU Restricted stock unit ESB Lease Agreement Office lease in the Empire State Building in NYC RTW RTW Investments, L.P ESG Environmental, Social and Governance SCD Sudden cardiac death EU European Union SEC Securities and Exchange Commission FA Fanconi Anemia Stanford Center for Definitive and Curative Medicine at Stanford University School of Medicine FANCA Fanconi Anemia Complementation Group A UCLA University of California, Los Angeles FDA U.S.
Food and Drug Administration UCLB UCL Business PLC FDCA Federal Food, Drug and Cosmetic Act UCSD The Regents of the University of California, San Diego FIBHNJS Fundaci n para la Investigacion Biom dica del Hospital del Nino Jesus UPC Unitary Patent Court FIISFJD Fundacion Instituto de Investigaci n Sanitaria Fundacion Jim nez D az U.S.
Generally Accepted Accounting Principles GDPR General Data Protection Regulation USPTO U.S.
These forward-looking statements include, but are not limited to, statements about: our ability to meet our anticipated milestones for our various drug candidates with respect to the initiation and timing of clinical studies; federal, state, and non-U.S.
These risks and uncertainties include, but are not limited to, the following: If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any of our product candidates, we may not be successful in commercializing those product candidates if and when they are approved.
We have never generated any revenue from product sales and may never be profitable.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →